The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Cited by
Sorted by citations
Items 501–600 of 726
Liu, K., Liu, J., Zhang, X., Liu, D., Yao, W., Bu, Y., & Chen, B. (2023) · BMC Cancer · doi:10.1186/s12885-023-11648-x · Cited by 7
Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma
Jung, E. E., Heinemann, F. S., Egelston, C. A., Wang, J. P., Pollock, R. E., Lee, P. P., & Tseng, W. W. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-228868 · Cited by 6
Li, L., Zhao, M., van Meurs, M., Brouwers-Haspels, I., den Dekker, R. J. H., Wilmsen, M. E. P., Grashof, D. G. B., van de Werken, H., Rao, S., Rokx, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509874 · Cited by 5
Niemann, B. R., Ivey, A. D., Hopen, Q., Dakhlallah, D. A., Brundage, K. M., Mihalik, N. E., Eubank, T. D., & Boone, B. A. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2601394 · Cited by 5
Dean, E. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1705345 · Cited by 5
Defining the cellular and molecular identities of histologic subtypes in lung adenocarcinoma
Lee, J., Jeong, J. Y., Hong, M. J., Choi, Y. H., Kim, J. Y., Lee, J. H., Choi, J. E., Kim, M., Do, Y. W., Lee, E. B., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00740-6 · Cited by 5
Meng, Z., Niu, X., Xia, L., Chen, Y., Wang, Z., Wang, H., Ji, P., Cui, W., Wang, Y., & Lü, S. (2023) · Advanced Biology · doi:10.1002/adbi.202200264 · Cited by 5
Mangana, C., & Maier, B. B. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.020 · Cited by 5
Effector and cytolytic function of natural killer cells in anticancer immunity
Karmakar, S., Mishra, A., Pal, P., & Lal, G. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad126 · Cited by 5
Baysal, M. A., Chakraborty, A., & Tsimberidou, A. M. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.080 · Cited by 4
The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function
Frey, A. (2017) · Cancer immunology research · doi:10.1158/2326-6066.cir-17-0187 · Cited by 4
Belizário, J. E., & Rodrigues, M. F. S. D. (2020) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135520904238 · Cited by 6
NKG2D defines tumor‐reacting effector CD8+ T cells within tumor microenvironment
Mojić, M., Shitaoka, K., Ohshima, C., Ucche, S., Lyu, F., Hamana, H., Tahara, H., Kishi, H., & Hayakawa, Y. (2021) · Cancer Science · doi:10.1111/cas.15050 · Cited by 5
Moore, C., Bae, J., Liu, L., Li, H., Fu, Y., & Qiao, J. (2022) · JCI Insight · doi:10.1172/jci.insight.159479 · Cited by 5
What do cancer-specific T cells ‘see’?
Shah, S., Al‐Omari, A., Cook, K., Paston, S. J., Durrant, L. G., & Brentville, V. A. (2022) · Discovery Immunology · doi:10.1093/discim/kyac011 · Cited by 6
Programmed T cell differentiation: Implications for transplantation
Crepeau, R. L., & Ford, M. L. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104099 · Cited by 5
The Development, Function, and Plasticity of the Immune Macroenvironment in CancerPreprint
Allen, B. M., Hiam-Galvez, K. J., Burnett, C. E., Venida, A. C., DeBarge, R., Carmi, Y., & Spitzer, M. H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/805473 · Cited by 5
PD-1 expression on NK cells can be related to cytokine stimulation and tissue residencyPreprint
Wagner, A. K., Kadri, N., Tibbitt, C. A., van de Ven, K., Singh, S. B., Oliinyk, D., LeGresly, E., Campbell, N., Trittel, S., Riese, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.29.437486 · Cited by 5
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responsesPreprint
Harris, R., Mammadli, M., Hiner, S., Suo, L., Yang, Q., Sen, J. M., & Karimi, M. A. (2022) · Research Square · doi:10.21203/rs.3.rs-1910637/v1 · Cited by 5
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control
Román, C. R. D., Erwin, M. M., Rudloff, M. W., Revetta, F. L., Murray, K. A., Favret, N. R., Roetman, J. J., Roland, J. T., Washington, M. K., & Philip, M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009129 · Cited by 4
Self-citationT Cell Dysfunction in the Acidic Tumor Microenvironment
Christiansen, F. B., Novella, E. S., Lindemann, A. V., Cordes, J. F. H., & Pedersen, S. F. (2026) · Acta Physiologica · doi:10.1111/apha.70260 · Cited by 4
Urabe, A., Chi, S., & Minami, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043727 · Cited by 4
Zhen, Y., Wang, H., Jiang, R., Wang, F., Chen, C., Xu, Z., & Xiao, R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1354533 · Cited by 4
Sierro-Martínez, B., Gómez, V. E., Pérez-Ortega, L., Guijarro-Albaladejo, B., Hernández-Díaz, P., de la Rosa-Garrido, M., Lara‐Chica, M., Rodríguez‐Gil, A., Reguera, J. L., Sanoja-Flores, L., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00984-0 · Cited by 5
Zhao, Y., Li, K., Sun, J., He, N., Zhao, P., Zang, C., Yang, X., Hu, C., Long, J., Zhang, H., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11636 · Cited by 4
Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro
Li, C., Li, Y., Lin, T., Zhang, Q., Zheng, F.-Y., & Mo, F. (2022) · Current Medical Science · doi:10.1007/s11596-022-2556-x · Cited by 4
Chen, Z., Lin, C., Pei, H., Yuan, X., Xu, J., Zou, M., Zhang, X., Fossier, A., Liu, M., Goo, S., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00480-4 · Cited by 5
Zhang, C., Adusei, M., Baranovic, A., DeBenedetto, M., Lauricella, A., Chilel-Martin, S., Newsom-Stewart, C. M., Schwartz, J., & Kurt, R. A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103929 · Cited by 4
Yu, H., Nishio, H., Barbi, J. J., Mitchell-Flack, M., Vignali, P., Zheng, Y., Lebid, A., Chang, K., Fu, J. L., Higgins, M., et al. (2024) · eLife · doi:10.7554/elife.96812.1.sa3 · Cited by 4
Immunoprevention of triple-negative breast cancer with a novel multivalent vaccine
Lee, S. B., Qian, J., Pan, J., Sei, S., Wang, Y., & You, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638526 · Cited by 3
T cell exhaustion landscapes and therapeutic modulation in cancer immunity
Bautista, J., & López‐Cortés, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1827716 · Cited by 5
Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives
Li, C. C., Liu, M., Lee, H.-P., Wu, W., & Ma, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1787152 · Cited by 3
Yao, Y., Liu, Y., Lu, B., Ji, G., Wang, L., Dong, K., Zhao, Z., Lyu, D., Wei, M., Tu, S., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01030-9 · Cited by 3
Hargadon, K. M., Goodloe, T. B., & Woodall, S. L. (2025) · Cancer Reports · doi:10.1002/cnr2.70145 · Cited by 3
Immune regeneration: implications for cancer immunotherapy and beyond
Reiner, S. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192731 · Cited by 3
Brummel, K., Requesens, M., van Rooij, N., Workel, H. H., Eggink, F. A., Plat, A., Wardenaar, R., Spierings, D. C. J., Foijer, F., Church, D. N., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0083 · Cited by 3
Venkatesh, H., Centeno, E. G., Luo, Q., Arroyo, M., Heltemes-Harris, L. M., Knutson, T. P., Qiu, Y., Haaning, A., Webber, B. R., Bachanová, V., et al. (2025) · Blood · doi:10.1182/blood.2024028194 · Cited by 4
Strategies for manufacturing cell therapy products aligned with patient needs
Guha, P., & Katz, S. C. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.11.003 · Cited by 3
TIL classified to memory state are correlated with response to immune checkpoint blockade
Jedema, I., & Haanen, J. B. A. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100669 · Cited by 3
Zhang, Y., Shi, C., Chen, Y., Wang, H., Chen, F., & Han, P. (2022) · Genes · doi:10.3390/genes13101897 · Cited by 3
493 Tired and hungry: a potential role for CD47 in T cell exhaustion
Mangarin, L. M. B., Liu, C., Zappasodi, R., Holland, P. M., Wolchok, J. D., Merghoub, T., Weng, C., Weng, C., & Schröder, D. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0493 · Cited by 3
Polania, J. W., Hoyt-Miggelbrink, A. M., Tomaszewski, W. H., Wachsmuth, L. P., Lorrey, S., Wilkinson, D. S., Lerner, E., Woroniecka, K. I., Finlay, J. B., Ayasoufi, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.11.553007 · Cited by 3
Immune Monitoring during Cancer Immunotherapy
Shehata, H. M., Dogra, P., & Sanjabi, S. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch105 · Cited by 3
Heterogeneous characteristics of γδ T cells in peripheral blood of diffuse large B-cell lymphoma
Wang, P., Lai, W., Zheng, J., Wu, X., Zhan, J., Yi, T., Jin, Z., & Wu, X. (2025) · Biomarker Research · doi:10.1186/s40364-025-00795-x · Cited by 4
Development of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Terasaki, F., Kumagai, S., Fukuda, A., Tanaka, Y., Irie, T., Ito, S., Yamada, M., Onoe, S., Mizuno, T., Kokuryo, T., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf065 · Cited by 2
Adoptive T‐cell therapies in the clinic
Shaha, S., Lourenco, L., Zhao, Z., & Mitragotri, S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70086 · Cited by 2
TOPK Suppresses the CD8 + T Cell Antitumor Immunity via Modulation of IRF5 Expression
Zang, N., Gan, J., Chen, Y., Huang, Z., Xie, C., Dang, J., Huang, C., Yang, L., Chen, X., Rong, G., et al. (2026) · 癌症：英文版 · doi:10.34133/cancomm.0021 · Cited by 2
Wang, C., Guo, Y., Han, F., Zhang, Y., Liu, C., Wu, Z., Tong, C., Yang, Q., Lu, Y., Zhong, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72040-4 · Cited by 2
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-718-5 · Cited by 3
DHA attenuates CAR-T cell efficacy through aggravating exhaustion and inducing apoptosis
Wang, Y., Zhao, Y., Zhu, Y., Xu, H., Zhao, W., Huang, C., Wang, B., Gao, X., Zhang, Q., Zheng, J., et al. (2023) · Biologia · doi:10.1007/s11756-023-01326-5 · Cited by 2
The road not taken en route to T cell exhaustion
Dash, B., & Hogan, P. G. (2023) · Nature Immunology · doi:10.1038/s41590-023-01596-w · Cited by 2
Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma
Li, C., Sun, C., Li, Y., Dong, L., Wang, X., Li, R., Su, J., Cao, Q., & Xin, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33764 · Cited by 2
CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients
Zhang, L., Cheng, R., Fan, Z., Liu, Y., Huang, J., & Peng, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1526772 · Cited by 3
Guo, J., Mu, D., & Han, Y. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.49 · Cited by 2
Modur, V., Muhammad, B. A., Yang, J.-Q., Zheng, Y., Komurov, K., & Guo, F. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112364 · Cited by 2
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
Rehm, A., Wirges, A., Hoser, D., Fischer, C., Herda, S., Gerlach, K., Sauer, S., Willimsky, G., & Höpken, U. E. (2022) · JCI Insight · doi:10.1172/jci.insight.155534 · Cited by 2
Persistent DNA Hyper-methylation Dampens Host Anti-Mycobacterial ImmunityPreprint
DiNardo, A. R., Rajapakshe, K., Nishiguchi, T., Mtetwa, G., Dlamini, Q., Kahari, J., Mahapatra, S., Kay, A. W., Maphalala, G. P., Mace, E. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/805457 · Cited by 2
T cell Egress via Lymphatic Vessels Limits the Intratumoral T cell Repertoire in MelanomaPreprint
Steele, M. M., Dryg, I. D., Murugan, D., Femel, J., du Bois, H., Hill, C. M., Leachman, S. A., Chang, Y. H., Coussens, L. M., & Lund, A. W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.30.494080 · Cited by 2
Su, K., Huang, X., Xu, K., Du, W., Zhu, D., Yang, M., Yuan, W., & Li, L. (2020) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000025 · Cited by 1
The Functional Adaptability of Hyporesponsive T Cells and Its Impact on Transplant Outcomes
Zou, D., Zhang, X., & Chen, W. (2023) · Current Transplantation Reports · doi:10.1007/s40472-023-00398-1 · Cited by 1
Draper, B., Bowers, C. E., Vassalou, E., Greppi, A., Anderson, J., Ahmed, N. M., Taylor, M. D., & Donovan, L. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103078 · Cited by 1
Nuclear Molecular Imaging for Evaluating T Cell Exhaustion
Zhou, H., Bao, G., Zhao, J., & Zhu, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00970 · Cited by 1
Cheng, H., Xiao, M., Zhang, Y., Wang, P., & Lu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-86338-8 · Cited by 1
A novel TOX-nanoluciferase reporter mouse for exploring modulators of T cell exhaustion
Li, L. V., Mueller, Y. M., Hioki, K., den Dekker, R. J. H., Brouwers-Haspels, I., Mezzanotte, L., Maas, A., Erkeland, S. J., & Katsikis, P. D. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf009 · Cited by 1
MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion
Mitra, T., Rahman, J. A., Hwee, M. A., Chen, Y.-T., Ramos, R. J. J. F., Liu, H., Hartman, T. E., Cross, J. R., de Jesus, M., Huse, M., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.06.012 · Cited by 1
Liu, Z., Li, H., Gao, Z., Cheng, R., Lu, J., Che, X., Dong, J., Wang, Z., Cui, Z., Gu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1684842 · Cited by 1
Saraç, H., Nicholson, R., Graham, R. N., Augustus, M., Taghavi, R., Connolly, D. J., Lim, L., & Lourenco, S. D. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1509926 · Cited by 1
Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity
Song, J., Cui, D., Wang, J., Qi, X., Ma, J., Liu, Q., Yang, J., Yu, H., Ye, L., Huang, Q., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20250424 · Cited by 1
Yu, S., Wu, P., Xie, X., Zhu, L. C., Chen, L., Yu, Y., Tan, W., Zhang, S., Wu, C. H., & Lin, D. X. (2026) · Science Advances · doi:10.1126/sciadv.aec9179 · Cited by 1
Pan, J., Li, B., Lin, R., Fang, C., Lau, L., Hong, Z., & Chen, Y. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5932 · Cited by 1
Tumor reactivity of CD8+ T cells favors acquisition of dysfunctional states in human melanoma
Hochheiser, K., Gyorki, D. E., & Gebhardt, T. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12498 · Cited by 1
Ramos‐Sevillano, E., & Yuste, J. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.10.28 · Cited by 1
Spear, S., McNeish, I. A., & Capasso, M. (2019) · Journal of Visualized Experiments · doi:10.3791/60622-v · Cited by 1
Tumor Microenvironment Complexity: A Pathological Milieu that Innately Modulates Cancer Progression
Balahura, L.-R., Lazăr, A. D., Dinescu, S., & Costache, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_89-1 · Cited by 2
Effects of folate deficiency and sex on carcinogenesis in a mouse model of oral cancer
Pitstick, L. D., Góral, J., Ciancio, M. J., Meyer, A., Pytynia, M., Bychek, S., Zidan, S., Shuey, J., Jham, B. C., & Green, J. M. (2023) · Oral Diseases · doi:10.1111/odi.14728 · Cited by 1
Yu, H., Nishio, H., Barbi, J. J., Mitchell-Flack, M., Vignali, P., Zheng, Y., Lebid, A., Chang, K., Fu, J. L., Higgins, M., et al. (2024) · eLife · doi:10.1101/2024.01.31.578284 · Cited by 1
Brandlmaier, M., Hoellwerth, M., Koelblinger, P., Lang, R., & Harrer, A. (2024) · Cancers · doi:10.3390/cancers16081461 · Cited by 2
CD112 is an epithelial-to-mesenchymal transition-related and immunological biomarker in pan-cancer
Zhang, H., Lü, J., Dong, Q., Wang, G., & Wang, X. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2258 · Cited by 1
LAGging behind no more: PD-1 has a new immunotherapy partner
Gunderson, A. J. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.010 · Cited by 1
Yang, Y.-L., Liu, R., Sun, Q., Chen, Z., & Fan, W. (2025) · Odontology · doi:10.1007/s10266-025-01202-5 · Cited by 1
Obesity-Induced Defects in Dendritic Cell and T Cell Functions
Orlandella, R. M., & Norian, L. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00012-5 · Cited by 1
Kleiman, E., Ouerkaxi, W., Delcommenne, M., Stone, G. W., Serafini, P., Tleugabulova, M. C., & Daftarian, P. M. (2020) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-0171-6_5 · Cited by 1
The Mechanisms of CD8+ T Cells Exhaustion in the Tumor Microenvironment and Immune Therapy
An, H., Song, S., & Huang, J. Y. (2023) · Journal of Cancer Therapy · doi:10.4236/jct.2023.144015 · Cited by 1
Impaired tumor death receptor signaling drives resistance to CAR T cell therapyPreprint
Singh, N., Shestova, O. E., Ravikumar, P., Hayer, K. E., Hong, S. J., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/627562 · Cited by 1
Prade, S., Wright, D., Logan, N., Teagle, A. R., Stauss, H. J., & Zamoyska, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.03.410043 · Cited by 1
Füchsl, F., Untch, J., Kavaka, V., Jarosch, S., Vogelsang, C., Krätzig, N. D. A., Gosmann, D., Rad, R., Busch, D. H., Beltrán, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.23.508529 · Cited by 1
Liao, X., Li, W., Li, A., Rajendran, B. K., Ren, J., Zhou, H., Calderwood, D., Turk, B. E., Tang, W., Liu, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.16.516824 · Cited by 1
Li, Y., Cui, Q., Liu, S., Liu, L., Li, M., Zhu, X., Kang, L., Yu, L., Cui, W., Tang, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3621440/v1 · Cited by 1
Maurice, N. J., Dalzell, T. S., Jarjour, N. N., DePauw, T. A., & Jameson, S. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.10.598293 · Cited by 1
Different signaling interpretations by PKC eta and theta control T cell function and exhaustionPreprint
Mann, T. H., Knox, H. M., Ma, S., Furgiuele, J., Globig, A.-M., LaPorta, M. A., Chung, H. K., McDonald, B., Ghassemian, M., Zhao, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.26.615103 · Cited by 1
Snyder, A. J., Shasha, C., Ho, T., Garrison, S. M., Wilhelm, A. R., Kluesner, M. G., Ortiz, S., Nutt, W. S., Bingham, E., Bhise, S. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648245 · Cited by 1
TCF1 lo CD8 T cells proliferate and persist autonomously in tumorsPreprint
Erwin, M. M., Favret, N. R., McDavid, C. N., Ewell, Z. D., Wolf, M. M., Brown, L. A., Roetman, J. J., Rudloff, M. W., Murray, K. A., Román, C. R. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.17.700120 · Cited by 1
Self-citationJo, Y., Karampatzakis, A., Lee, S. W., Peng, A., Ghouri, Z., Moya, M., Andrews, E., Sudholz, H., Zhang, C., Tayeh, B. B., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7169781 · Cited by 1
Medrano, R. F. V. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-06042018-122815
Defining Neoepitopes that Contribute to Tumor Immunity
Brennick, C. A. (2018) · OpenCommons - UConn (University of Connecticut)
rPCMP: robust p-value combination by multiple partitions with applications to ATAC-seq data
Cai, M., & Li, L. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0661-z
Scott, A. N. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-j47p-0v68
CAR T-Cell Therapy for CNS Malignancies
Sanber, K. S., Joseph, S. K., & Ahmed, N. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00012-3
Liu, Z., Li, J., Chen, M., Wu, M., Shi, Y., Li, W., Teijaro, J. R., & Wu, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.18.996017
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
